Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.

碩士 === 國立臺灣大學 === 生化科技學系 === 104 === The Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported to infect human beings in September 2012. This virus seemed to develop into a highly contagious disease and caused high mortality rate up to 36%. Since December 2013 west Africa experi...

Full description

Bibliographic Details
Main Authors: Chih-Chi Li, 黎芷琪
Other Authors: 莊榮輝
Format: Others
Language:zh-TW
Published: 2016
Online Access:http://ndltd.ncl.edu.tw/handle/25944085674389179428
id ndltd-TW-104NTU05106107
record_format oai_dc
spelling ndltd-TW-104NTU051061072017-05-14T04:32:18Z http://ndltd.ncl.edu.tw/handle/25944085674389179428 Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses. 發展新興傳染病毒膜醣蛋白之中和性單株抗體 Chih-Chi Li 黎芷琪 碩士 國立臺灣大學 生化科技學系 104 The Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported to infect human beings in September 2012. This virus seemed to develop into a highly contagious disease and caused high mortality rate up to 36%. Since December 2013 west Africa experienced the largest outbreak of Ebola, which was first discovered in 1976. The mortality of Ebola virus disease is relatively high, and yet the therapeutic drugs and vaccines are still under development. Researches for further understanding of the disease progression as well as accurate detection methods for these viruses are important for endemic control. Thus, the goal of this study is to develop specific antibodies against Ebola virus or MERS-CoV for the application in virus detection and clinical therapy. Two of the virus surface proteins, glycoprotein(GP)and spike protein(SP), which were predicted as having high specificity and antigenicity were chosen as the antigens. In Ebola case, 3 peptides fragments of GP and its truncated form, constructed in refer to the published anti-GP mAb KZ52, were synthesized and expressed for mice immunization. In MERS-CoV case, S1 domain and receptor binding domain(RBD)were constructed and expressed in Bac-to-Bac Expression system for immunization. After repeat boosts, mice were sacrificed for producing hybridoma. Monoclonal antibodies(mAb) were screened by enzyme-linked immunosorbent assay(ELISA)and then identified by Western blot. Finally, neutralizing assays for MERS-CoV were used to verify the inhibition of the specific mAb which might block the virus invasion through the expressed DPP4 receptor on the cell surface. Useful mAb will be selected and used to develop the blocking ELISA or the antigen-capture ELISA, which could be utilized in clinical diagnosis or quick viral detection in the field. 莊榮輝 2016 學位論文 ; thesis 115 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國立臺灣大學 === 生化科技學系 === 104 === The Middle East respiratory syndrome coronavirus (MERS-CoV) was first reported to infect human beings in September 2012. This virus seemed to develop into a highly contagious disease and caused high mortality rate up to 36%. Since December 2013 west Africa experienced the largest outbreak of Ebola, which was first discovered in 1976. The mortality of Ebola virus disease is relatively high, and yet the therapeutic drugs and vaccines are still under development. Researches for further understanding of the disease progression as well as accurate detection methods for these viruses are important for endemic control. Thus, the goal of this study is to develop specific antibodies against Ebola virus or MERS-CoV for the application in virus detection and clinical therapy. Two of the virus surface proteins, glycoprotein(GP)and spike protein(SP), which were predicted as having high specificity and antigenicity were chosen as the antigens. In Ebola case, 3 peptides fragments of GP and its truncated form, constructed in refer to the published anti-GP mAb KZ52, were synthesized and expressed for mice immunization. In MERS-CoV case, S1 domain and receptor binding domain(RBD)were constructed and expressed in Bac-to-Bac Expression system for immunization. After repeat boosts, mice were sacrificed for producing hybridoma. Monoclonal antibodies(mAb) were screened by enzyme-linked immunosorbent assay(ELISA)and then identified by Western blot. Finally, neutralizing assays for MERS-CoV were used to verify the inhibition of the specific mAb which might block the virus invasion through the expressed DPP4 receptor on the cell surface. Useful mAb will be selected and used to develop the blocking ELISA or the antigen-capture ELISA, which could be utilized in clinical diagnosis or quick viral detection in the field.
author2 莊榮輝
author_facet 莊榮輝
Chih-Chi Li
黎芷琪
author Chih-Chi Li
黎芷琪
spellingShingle Chih-Chi Li
黎芷琪
Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
author_sort Chih-Chi Li
title Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
title_short Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
title_full Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
title_fullStr Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
title_full_unstemmed Development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
title_sort development of neutralizing antibody against the membrane glycoproteins of emerging disease viruses.
publishDate 2016
url http://ndltd.ncl.edu.tw/handle/25944085674389179428
work_keys_str_mv AT chihchili developmentofneutralizingantibodyagainstthemembraneglycoproteinsofemergingdiseaseviruses
AT lízhǐqí developmentofneutralizingantibodyagainstthemembraneglycoproteinsofemergingdiseaseviruses
AT chihchili fāzhǎnxīnxìngchuánrǎnbìngdúmótángdànbáizhīzhōnghéxìngdānzhūkàngtǐ
AT lízhǐqí fāzhǎnxīnxìngchuánrǎnbìngdúmótángdànbáizhīzhōnghéxìngdānzhūkàngtǐ
_version_ 1718449288819769344